Nurosene Health Inc.
MNNDF
Other OTC0.33
USD
-0.03
- -
Return %
Stock
S&P500
1Y
-24.42
26.53
3Y
-74.08
76.60
5Y
-74.08
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- George Achilleos
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 1655 Dupont Street Toronto ON Canada M6P 3T1
- IPO Date
- Sep 20, 2021
- Website
- nurosene.com
- Similar Companies
- Business
- NetraMark Holdings Inc. NetraMark Holdings Inc. (formerly Nurosene Health Inc. ) operates as an AI healthtech company that leverages proprietary artificial intelligence algorithms to analyze clinical trial data for pharmaceutical and biotechnology clients, identifying undiscovered subpopulations driving drug response, placebo response, and adverse events to inform trial enrichment strategies and prevent failures. The company offers NetraAI Lab, a four-week analysis service for single clinical-stage assets covering efficacy, toxicity, and placebo inquiries with deliverables including effect size simulations, p-value projections, and protocol recommendations; NetraAI Pivotal Decision Support for Phase II data to support pivotal studies via patient stratification, placebo mitigation, biomarker support, and drug repurposing through NetraPlay access populated with proprietary datasets like the Netra Health Atlas; and the Treatment Attitude Profile (TAP) scale for placebo response assessment. NetraAI, powered by Attractor AI—a novel long-range attractor algorithm—excels in high-dimensional, small-sample datasets such as RNASeq, microarray, SNP, and methylation data, generating hypotheses on causal variables for patient profiles in areas including oncology, neurodegenerative diseases, psychiatry, Alzheimer's, Parkinson's, schizophrenia, ALS, NSCLC, and colorectal cancer. Founded in 2019 and headquartered at 1655 Dupont Street, Suite 101, Toronto, Ontario, with a registered office in Vancouver, British Columbia, the company acquired NetraMark Corp. in October 2021, pivoting from consumer wellness supplements and the Nuro app to pharma-tech AI solutions; it changed its name to NetraMark Holdings Inc. on February 1, 2023, and trades under CSE: AIAI, Frankfurt: 8TV, and OTC: AINMF. Recent developments include signing contracts worth $1M CDN with leading biopharmaceutical companies starting revenue recognition in fiscal Q1 2024; entering a research collaboration with the U.S. National Institute of Mental Health (NIMH); launching NetraAI Lab in 2024; presenting data at conferences such as AACR, AD/PD, ISCTM, and AAIC on biomarkers, subtypes, and placebo modeling; publishing peer-reviewed papers on lung cancer, ALS, and psychiatric trials; developing partnerships with contract research organizations; and appointing key executives like Chief Medical Officer Dr. Larry Alphs in November 2023 and advisors including Abhishek Agrawal and Jeff Huntsman.